{"disease":{"id":"deep-venous-thrombosis","name":"Deep venous thrombosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":15,"pipeline_drug_count":0,"trial_count":2},"drugs":{"marketed":[{"drug_id":"chembl-chembl48361","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran Etexilate","generic_name":"DABIGATRAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":"1200","mechanism":"Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"chembl-chembl48361","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran Etexilate","generic_name":"DABIGATRAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":"1200","mechanism":"Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"bemiparin","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"BEMIPARIN","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Factor Xa and thrombin (via antithrombin III enhancement)","drug_class":"Low Molecular Weight Heparin","quality_score":0,"revenue":null,"mechanism":"Fragmin works by binding to and activating antithrombin, which inhibits the coagulation cascade."},{"drug_id":"fondaparinux","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arixtra","generic_name":"FONDAPARINUX","company_name":"Mylan Ireland Ltd","drug_phase":"marketed","molecular_target":"Coagulation factor X","drug_class":"Factor Xa Inhibitor","quality_score":67,"revenue":null,"mechanism":"Arixtra works by blocking the action of factor Xa, a protein involved in blood clotting."},{"drug_id":"enoxaparin-sodium","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lovenox (Preservative Free)","generic_name":"ENOXAPARIN SODIUM","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Low Molecular Weight Heparin","quality_score":10,"revenue":null,"mechanism":"Lovenox works by enhancing the activity of antithrombin-III to inhibit blood clotting."},{"drug_id":"heparin","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"HEPARIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Anti-coagulant","quality_score":56,"revenue":null,"mechanism":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots."},{"drug_id":"rivaroxaban","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xarelto","generic_name":"rivaroxaban","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Direct Factor Xa Inhibitor","quality_score":71,"revenue":null,"mechanism":"Selective FXa inhibitor that decreases thrombin generation without requiring cofactors."},{"drug_id":"heparin-sodium","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"Heparin Sodium","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Antithrombin III, Coagulation Factors Xa and IIa","drug_class":"Anticoagulant","quality_score":63,"revenue":null,"mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa."},{"drug_id":"warfarin","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coumadin","generic_name":"warfarin","company_name":"Generic (originally Wisconsin Alumni Research Foundation)","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7","drug_class":"Vitamin K antagonist (anticoagulant)","quality_score":60,"revenue":null,"mechanism":"Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis."},{"drug_id":"nadroparin-calcium","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fraxiparin","generic_name":"NADROPARIN CALCIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"arixtra","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Arixtra","company_name":"LifeBridge Health","drug_phase":"marketed","molecular_target":"Antithrombin-III, Coagulation factor X","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lovenox","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lovenox","company_name":"University of Monastir","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"enoxaparin","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Enoxaparin","company_name":"Dana-Farber Cancer Institute","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xarelto","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xarelto","company_name":"University Hospital, Montpellier","drug_phase":"marketed","molecular_target":"Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fraxiparine","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fraxiparine","company_name":"Leiden University Medical Center","drug_phase":"phase_1","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"nadroparin","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"nadroparin","company_name":"Onze Lieve Vrouwe Gasthuis","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":16,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03271450","title":"The DARE Warfarin CER Study","phase":"","overall_status":"UNKNOWN","enrollment_count":416000,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT02943343","title":"The China Pulmonary Thromboembolism Registry Study","phase":"","overall_status":"UNKNOWN","enrollment_count":15000,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT02598609","title":"SEPREVEN: a Stepped-wedge Randomised Controlled Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":8000,"lead_sponsor_name":"Dr Caeymaex Laurence","has_results":false},{"nct_id":"NCT04211181","title":"CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism","phase":"NA","overall_status":"RECRUITING","enrollment_count":5800,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT03881345","title":"Ongoing Registry of Treatment of Venous Thromboembolism","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Medalp Private Surgery Clinic","has_results":false},{"nct_id":"NCT04158973","title":"CHIPs-VTE Study in Hospitalized Patients With Lung Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":3200,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT02040103","title":"Pneumatic Compression for Preventing Venous Thromboembolism","phase":"NA","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"King Abdullah International Medical Research Center","has_results":false},{"nct_id":"NCT05171049","title":"A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1150,"lead_sponsor_name":"Anthos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT01828697","title":"Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1110,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT02211326","title":"Genotype-guided Warfarin Individualized Treatment","phase":"NA","overall_status":"COMPLETED","enrollment_count":660,"lead_sponsor_name":"The Third Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT03937583","title":"Screening for Cancer in Patients With Unprovoked VTE","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":650,"lead_sponsor_name":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","has_results":false},{"nct_id":"NCT03006562","title":"PREvention of VENous ThromboEmbolism Following Radical Prostatectomy","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":501,"lead_sponsor_name":"Johns Hopkins University","has_results":true},{"nct_id":"NCT05171075","title":"A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":417,"lead_sponsor_name":"Anthos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03740633","title":"Functional Training for the Prevention of Deep Venous Thrombosis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":398,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT05701917","title":"DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Inari Medical","has_results":false},{"nct_id":"NCT03212365","title":"Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":295,"lead_sponsor_name":"University of Utah","has_results":true},{"nct_id":"NCT07399977","title":"Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism","phase":"NA","overall_status":"RECRUITING","enrollment_count":259,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT04924322","title":"Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":258,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT04414332","title":"Registry of Angiovac Procedures In Detail Outcomes Database-RAPID Registry","phase":"","overall_status":"COMPLETED","enrollment_count":234,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT04374617","title":"Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":230,"lead_sponsor_name":"Hospital Universitari Vall d'Hebron Research Institute","has_results":false},{"nct_id":"NCT03286985","title":"The Prevalence and Incidence of DVT in General ICU","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Masaryk Hospital Krajská zdravotní a.s.","has_results":false},{"nct_id":"NCT03251963","title":"Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":131,"lead_sponsor_name":"University of Utah","has_results":true},{"nct_id":"NCT03296280","title":"Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program","phase":"","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT03707665","title":"Deep Venous Thrombosis Screening in the ICU by Nurses","phase":"","overall_status":"COMPLETED","enrollment_count":115,"lead_sponsor_name":"Emergency Medical Service of the Central Bohemian Region, Czech Republic","has_results":false},{"nct_id":"NCT05827120","title":"Endovascular Therapy in Patients With Acute Deep Vein Thrombosis","phase":"","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"National Institute of Cardiovascular Diseases, Slovakia","has_results":false},{"nct_id":"NCT03506815","title":"Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"Ottawa Hospital Research Institute","has_results":true},{"nct_id":"NCT05588284","title":"Preservation of Venous Valvular Function After PMT for Acute DVT","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100,"lead_sponsor_name":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","has_results":false},{"nct_id":"NCT06486181","title":"Second Line Endovascular Treatment in Acute DVT","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Rush University Medical Center","has_results":false},{"nct_id":"NCT06913595","title":"Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT04979026","title":"Clinical Investigation of a Novel Approach for the Prevention of Deep Venous Thrombosis After Total Knee Replacement","phase":"NA","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Show Chwan Memorial Hospital","has_results":false},{"nct_id":"NCT07281638","title":"Bedside Bike Early Mobilization Program for Inpatients","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT01721928","title":"Norwegian Intensive Care Unit Dalteparin Effect Study","phase":"","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT05303818","title":"Chemoprophylaxis With Rivaroxaban for Lower Limb Deep Vein Thrombosis in Colorectal Cancer","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":68,"lead_sponsor_name":"Hospital do Servidor Publico Estadual","has_results":false},{"nct_id":"NCT06495996","title":"The Protrieve PROTECTOR Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Inari Medical","has_results":false},{"nct_id":"NCT03026049","title":"Stent Versus Conservative Treatment in Patients With Deep Venous Obstruction","phase":"NA","overall_status":"TERMINATED","enrollment_count":65,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT02945280","title":"Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":52,"lead_sponsor_name":"Intermountain Health Care, Inc.","has_results":false},{"nct_id":"NCT03195777","title":"Novel PET/CT and Treatment Strategies to Reduce PTS Following DVT","phase":"NA","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT03003390","title":"Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":51,"lead_sponsor_name":"Yale University","has_results":true},{"nct_id":"NCT03328624","title":"A Preliminary Clinical Usability Study for the Recovery Force DVT II Cuff","phase":"NA","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"University of Southern California","has_results":true},{"nct_id":"NCT04452422","title":"Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology","phase":"","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT02719418","title":"Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses","phase":"","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Maisonneuve-Rosemont Hospital","has_results":false},{"nct_id":"NCT03038893","title":"Point of Care Ultrasound For The Diagnosis Of Deep Venous Thrombosis And Its Effect On Length Of Hospital Stay","phase":"NA","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Hospital de Clinicas de Porto Alegre","has_results":false},{"nct_id":"NCT02970032","title":"Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose Heparin","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"University of Utah","has_results":true},{"nct_id":"NCT06042686","title":"Venous Thrombosis Prevention and Sleep Quality: A Comparison of the Kendall and the Recovery Health MAC Systems","phase":"NA","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"University of Massachusetts, Amherst","has_results":false},{"nct_id":"NCT03050671","title":"Effects of External Leg Compression Devices on Healing and Blood Clotting","phase":"NA","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Karolinska University Hospital","has_results":false},{"nct_id":"NCT03420664","title":"Comparison of the Effects of Lower Limb Immobilisation With Cast and Orthosis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Karolinska University Hospital","has_results":false},{"nct_id":"NCT04232501","title":"Radial, Sequential Compression Device Deep Venous Thrombosis Detection Study","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT05288413","title":"Benefit of Machine Learning to Diagnose Deep Vein Thrombosis Compared to Gold Standard Ultrasound","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT04411316","title":"Catheter-directed Thrombolysis Compared to Anticoagulation Alone for Acute Primary Iliofemoral Deep Venous Thrombosis","phase":"PHASE4","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Toledo Health Science Campus","has_results":false}],"total":49},"guidelines":[{"drug_id":"heparin-sodium-25-000-units-in-dextrose-5-in-plastic-container","guideline_body":"FDA label","recommendation":"Prophylaxis and treatment of venous thrombosis","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"heparin-sodium-10-000-units-in-dextrose-5-in-plastic-container","guideline_body":"FDA label","recommendation":"Prophylaxis and treatment of venous thrombosis","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"heparin-sodium-12-500-units-in-dextrose-5-in-plastic-container","guideline_body":"FDA label","recommendation":"Prophylaxis and treatment of venous thrombosis","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"heparin-sodium-preservative-free","guideline_body":"FDA label","recommendation":"Prophylaxis and treatment of venous thrombosis","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"heparin-sodium","guideline_body":"FDA label","recommendation":"Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null}],"source":"Drug Landscape verified database"}